

SCI PHARMTECH, INC. 旭富製藥科技

簡報

ISO 14001

BUREAU VERITAS
Certification



ISO 9001

BUREAU VERITAS
Certification



公司概況Profile

📄 產能Capacity：

2021:0，2022:5～35%，2023:35～65%，2024 Feb.: completed

📄 員工數Employee：255

📄 設立日期：中華民國七十六年九月十八日

Date of establishment: Sep. 18, 1987

📄 資本額Capital：新台幣1,195佰萬元(NTD 1,195mn)

📄 營業項目Business：

原料藥API (59.65%)

中間體Intermediate (39.17%)

其他 Other chemicals (1.18%)

產品組合-Products

Sales Product	%	2023Y (K NT\$)
PGA	26.0%	313,184
VA series	25.2%	303,219
Pent-2 / PEB.Na	24.4%	293,838
BZA	8.3%	100,190
Dulo.Hcl	5.4%	65,168
PF.Hcl	4.0%	47,786

營運概況-IS

Unit: K NTD


	2023.Q1~Q3
營收Sales	912,743
營業成本COGS	(629,815)
毛利Gross Profit	282,928
毛利率 GP Ratio	31.0%
營業費用Operating Expenses	(131,539)
營業利益Operating Income	151,389
營業外損益Non-Operating In/Ex	223,094
稅前淨利 Net Profit before Tax	374,483
所得稅Income Tax	(76,151)
本期淨利Net Profit after Tax	298,332

Pyrogallolaldehyde (PGA)

Benserazide

治療帕金森氏症之中間體


Intermediate for Parkinson's Disease



VA Series:

Valproic Acid, Divalproex Sodium, Sodium Valproate


- 適應症 Application :
癲癇(seizure)、躁鬱症(bipolar disorder)、
偏頭痛(migraine headaches)



Pent-2 / Pentobarbital Sodium

鎮定安眠用中間體及原料藥


Intermediate and API for calmative



Brinzolamide

- 青光眼原料藥


API for Glaucoma medication



Duloxetine HCl

- 適應症 Application:


重鬱症(major depressive disorder)、廣泛性焦慮症
(generalized anxiety disorder)、糖尿病週邊神經痛
(diabetic neuropathy)、纖維肌痛 (Fibromyalgia)、
慢性腰痛(日本地區) lower back pain (only in Japan)



Hydroxychloroquine sulfate

- 適應症 Application:

類風濕性關節炎(rheumatoid arthritis)、瘧疾(malaria)、慢性多形性日光疹、慢性圓板狀紅斑症(discoid and systemic lupus erythematosus)



新品項(New Products)

- Buprenorphine
止痛劑(Painkiller) 、治療鴉片類物質成癮 (Opioid use addiction)
- LMTM
阿茲海默症藥物(Alzheimer's disease medicine)
- 大麻二酚 Cannabidiol
癲癇藥物 (Epidiolex)
- 嗜睡症藥物 (Narcolepsy)
- 腺嘌呤 (Adenine)
- Pimobendan
寵物心臟病藥物(Heart disease medicine for pets)

觀音廠&法蘭摩沙(Guanyin Plant and Framosa)

預計2025年量產

Both will be commercialized in 2025



General View

簡報完畢



敬請指教